Editor: What To Know
- announced that clinical data from the company’s PURE EP System, a biomedical signal processing platform designed to improve the efficacy and efficiency of ablation procedures, will be featured in two presentations (abstracts) at the annual Heart Rhythm 2021 convention.
- The company completed enrollment for its second multi-center clinical trial in April 2021 and looks forward to sharing PURE EP’s most recent clinical data in-person at the Heart Rhythm 2021 convention on July 28-31, 2021.
- , of Deborah Heart and Lung Center in Browns Mills, New Jersey, is titled, “Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion.
BioSig Technologies, Inc. announced that clinical data from the company’s PURE EP System, a biomedical signal processing platform designed to improve the efficacy and efficiency of ablation procedures, will be featured in two presentations (abstracts) at the annual Heart Rhythm 2021 convention
The first presentation was co-authored by Pedram Kazemian, M.D. et al., of Deborah Heart and Lung Center in Browns Mills, New Jersey, is titled, “Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion.”
The second abstract was co-authored by Jonathan Salas, B.S.; Pasquale Santangeli, M.D.; David Callans, M.D.; Francis E. Marchlinski, M.D.; Cory M. Tschabrunn, Ph.D. of University of Pennsylvania in Philadelphia, Pennsylvania, is titled, “Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude and Morphology During Radiofrequency Ablation.”
BioSig’s PURE EP System is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals during complex ablation procedures.
The company completed enrollment for its second multi-center clinical trial in April 2021 and looks forward to sharing PURE EP’s most recent clinical data in-person at the Heart Rhythm 2021 convention on July 28-31, 2021.
